{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T16:45:19Z","timestamp":1782665119104,"version":"3.54.5"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403971"],"award-info":[{"award-number":["82403971"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.lungcan.2026.109409","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:08:20Z","timestamp":1775840900000},"page":"109409","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Surgery after neoadjuvant immunochemotherapy versus immuno-chemoradiotherapy in patients with cN3 non-small cell lung cancer: A cohort study in two academic centers"],"prefix":"10.1016","volume":"216","author":[{"given":"Wenyu","family":"Zhai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dachuan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqin","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6604-7811","authenticated-orcid":false,"given":"Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wingshing","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109409_b0005","article-title":"The IASLC lung cancer staging project: proposals for revision of the TNM stage groups in the forthcoming (ninth) edition of the TNM classification for lung cancer","author":"Rami-Porta","year":"2024","journal-title":"J. Thorac. Oncol. Off. Pub. Int. Assoc. Study Lung Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109409_b0010","first-page":"752","article-title":"Risk stratification and adjuvant chemotherapy after radical resection based on the clinical risk scores of patients with stage IB-IIA non-small cell lung cancer","volume":"48","author":"Zhai","year":"2022","journal-title":"European J. Surg. Oncol. J. European Soc. Surg. Oncol. British Assoc. Surg. Oncol."},{"issue":"5 Suppl","key":"10.1016\/j.lungcan.2026.109409_b0015","doi-asserted-by":"crossref","first-page":"e314S","DOI":"10.1378\/chest.12-2360","article-title":"Treatment of stage III non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines","volume":"143","author":"Ramnath","year":"2013","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109409_b0020","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jtho.2019.10.022","article-title":"Asian thoracic oncology research group expert consensus statement on optimal management of stage III NSCLC","volume":"15","author":"Tan","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"25","key":"10.1016\/j.lungcan.2026.109409_b0025","doi-asserted-by":"crossref","first-page":"5910","DOI":"10.1200\/JCO.2005.03.070","article-title":"Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Fran\u00e7ais de Pneumo-Canc\u00e9rologie NPC 95-01 Study","volume":"23","author":"Fournel","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109409_b0030","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1470-2045(09)70172-X","article-title":"Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol."},{"issue":"20","key":"10.1016\/j.lungcan.2026.109409_b0035","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109409_b0040","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109409_b0045","doi-asserted-by":"crossref","unstructured":"Reck M, Lee KH, Frost N, Breder VV, Kowalski D, Levchenko E, et al. Two-year update from KEYNOTE-799: Pembrolizumab plus concurrent chemoradiation therapy (cCRT) for unresectable, locally advanced, stage III NSCLC. 2022;40(16_suppl):8508-.","DOI":"10.1200\/JCO.2022.40.16_suppl.8508"},{"key":"10.1016\/j.lungcan.2026.109409_b0050","doi-asserted-by":"crossref","unstructured":"Ross HJ, Kozono DE, Urbanic JJ, Williams TM, DuFrane C, Bara I, et al. AFT-16: Phase II trial of neoadjuvant and adjuvant atezolizumab and chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC). Journal of Clinical Oncology.39(15_suppl):8513-.","DOI":"10.1200\/JCO.2021.39.15_suppl.8513"},{"issue":"21","key":"10.1016\/j.lungcan.2026.109409_b0055","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.lungcan.2026.109409_b0060","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative nivolumab in resectable lung cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109409_b0065","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S2213-2600(24)00269-8","article-title":"Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial","volume":"13","author":"Yue","year":"2025","journal-title":"Lancet Respir. Med."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109409_b0070","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005160","article-title":"Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysis","volume":"10","author":"Zhai","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.lungcan.2026.109409_b0075","article-title":"Safety and necessity of omitting mediastinal lymph node dissection in cN0\/N1 non-small cell lung cancer after neoadjuvant immunotherapy","volume":"16","author":"Zhou","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109409_b0080","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41392-024-01861-w","article-title":"Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II-III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study","volume":"9","author":"Xia","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109409_b0085","doi-asserted-by":"crossref","first-page":"e600","DOI":"10.1097\/SLA.0000000000005233","article-title":"Radical minimally invasive surgery after immuno-chemotherapy in initially-unresectable stage IIIB non-small cell lung cancer","volume":"275","author":"Deng","year":"2022","journal-title":"Ann. Surg."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109409_b0090","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jtho.2020.01.005","article-title":"IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy","volume":"15","author":"Travis","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109409_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107326","article-title":"Efficacy and surgical safety of sequential surgical resection after pembrolizumab plus chemotherapy for initial unresectable stage IIIB non-small cell lung cancer","volume":"184","author":"Zheng","year":"2023","journal-title":"Lung Cancer (amsterdam, Netherlands)."},{"key":"10.1016\/j.lungcan.2026.109409_b0100","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2025.1115","article-title":"Neoadjuvant PD-1 and PD-L1 blockade with chemotherapy for borderline resectable and unresectable stage III non-small cell lung cancer","author":"Ricciuti","year":"2025","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2026.109409_b0105","doi-asserted-by":"crossref","unstructured":"Zhou Q, Pan Y, Yang X, Zhao Y, Han G, Pang Q, et al. Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial. Cancer cell. 2024;42(7):1258-67.e2.","DOI":"10.1016\/j.ccell.2024.05.024"},{"issue":"142","key":"10.1016\/j.lungcan.2026.109409_b0110","first-page":"83","article-title":"Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: a real-world multicentre study. European journal of cancer (Oxford","volume":"2021","author":"Desilets","year":"1990","journal-title":"England"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109409_b0115","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jtho.2022.10.003","article-title":"Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R study","volume":"18","author":"Girard","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109409_b0120","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1515\/jtim-2025-0052","article-title":"A signature of plasma exosomal miRNAs predict therapeutic efficacy to neoadjuvant immunotherapy in patients with non-small cell lung cancer","volume":"13","author":"Zhai","year":"2025","journal-title":"J. Trans. Internal Med."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T16:21:02Z","timestamp":1782663662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226004708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":24,"alternative-id":["S0169500226004708"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109409","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Surgery after neoadjuvant immunochemotherapy versus immuno-chemoradiotherapy in patients with cN3 non-small cell lung cancer: A cohort study in two academic centers","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109409","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109409"}}